GlassScriptPhysician profile
Andrew C Mcafee
NPI 1558395079
$13,949.28
in general payments reported to CMS, 2019-2025
59 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,747 · 2020: $1,468 · 2021: $1,831 · 2022: $2,553 · 2023: $2,389 · 2024: $2,306 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,284 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,283.66 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,724.83 | 2019-2025 | |
| Novo Nordisk INC | $1,645.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,367.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $851.02 | 2019-2025 | |
| Lilly USA, LLC | $736.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $728.26 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $721.01 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $572.11 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $455.64 | 2019-2023 | Trintellix |
| Corium, LLC | $454.46 | 2022-2025 | Azstarys |
| Astellas Pharma US INC | $419.49 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $381.52 | 2019-2022 | |
| Amgen INC. | $380.57 | 2019-2024 | Otezla, Repatha, Evenity |
| Abbott Laboratories | $357.49 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $279.09 | 2019-2023 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mcafee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.